Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blue Water Ventures International Inc (OP: BWVI )

0.0139 +0.0029 (+26.36%)
Streaming Delayed Price Updated: 12:37 PM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Blue Water Ventures International Inc

< Previous 1 2 Next >
Psychedelics 2024: Veterans Blessing, Mental Health Paradigm Shift, Providers Training, Ketamine-MDMA Bonds & More
Via Benzinga
Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
Via Benzinga
Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space
Via ACCESSWIRE
Dr. Neilank Jha Appointed as Executive Chairman and Chief Executive Officer of Psycheceutical Bioscience Inc.
Via ACCESSWIRE
Shark Tank's Kevin Harrington Leads Crowdfunding Campaign For Psycheceutical Bioscience (OTCPK: BWVI)
Shark Tank’s Kevin Harrington thinks safe psychedelic medicines without the “trip” are the future of mental health care, and has put his support behind Psycheceutical - Click Here To Invest 
Via Benzinga
Psycheceutical Bioscience Launches Wefunder Crowdfunding Campaign for Safer Psychedelic Dosing
Via ACCESSWIRE
Treating PTSD Topically & Directly To The Brain? Psychedelics Delivery Company Poised For Major Breakthrough
Psycheceutical Bioscience, Inc (OTCPK: BWVI) is a cutting-edge biotech startup that developed a topical drug delivery system called NeuroDirect, a system that can be used to deliver psychedelic drugs... 
Via Benzinga
Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect Ketamine for PTSD
Via ACCESSWIRE
Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy
Via ACCESSWIRE
First Patient Dosed in Psycheceutical's Phase I Study Exploring Topical Administration of Ketamine to Treat PTSD
Via ACCESSWIRE
Video: 'Moms On Mushrooms Are Gonna Change The Whole Society,' Says Zappy Zapolin Before Presenting Rick Doblin Award
In a moment of riveting candor at MAPS' Psychedelic Science 2023 conference in Denver, Colorado, Benzinga Cannabis' Lara Goldstein captured the potent essence of Psycheceutical Bioscience Inc (OTC: 
Via Benzinga
EXCLUSIVE: Lessons From Psychedelics Markets Through Business, Legal And Reciprocity Lenses
This year’s edition of Benzinga’s Psychedelics Capital Conference hosted some of the most knowledgeable panelists and hot-button discussions currently in the space. 
Via Benzinga
Zappy Zapolin Talks Psychedelics And Breakthrough Delivery Methods: The Future Has Arrived And It's Awesome
Mike ‘Zappy’ Zapolin, Chief Visionary Officer of Psycheceutical Bioscience, Inc (OTCPK: BWVI), whom we'll call Zappy, shared his vision for the future of psychedelics at the... 
Via Benzinga
The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.’s (OTCPK:BWVI) Novel Topical Ketamine Delivery
Via ACCESSWIRE
Psyched: MDMA Therapy Advances With FDA, Alternatives For Alcohol Addiction, Prince Harry In The Spotlight And More
MDMA Therapy For PTSD Nearing Legalization In U.S. And Worldwide, MAPS Releases Promising Data 
Via Benzinga
This Groundbreaking Ketamine Topical Cream Is Capturing Rick Doblin's Attention
Psycheceutical Bioscience (OTC: BWVI), a company focused on developing innovative technologies for the next generation of mental health treatments, recently hosted Rick Doblin, founder and president of... 
Via Benzinga
What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry
The world of psychedelics is evolving rapidly, and the Benzinga Psychedelics Capital Conference is the premier event for those who want to be part of this exciting journey. 
Via Benzinga
Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab
Doblin commented on the potential of the company’s NeuroDirect™ ketamine topical cream to help those suffering from PTSD 
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
What If There Was A Topical Cream That Treated PTSD Without Side Effects? — Psycheceutical Bioscience, Inc (OTCPK: BWVI) Is Pioneering A Possible Solution
What If There Was A Topical Cream That Treated PTSD Without Side Effects? — Psycheceutical Bioscience, Inc (OTCPK: BWVI) Is Pioneering A Possible Solution 
Via News Direct
What If There Was A Topical Cream That Treated PTSD Without Side Effects? — Psycheceutical Bioscience, Inc (OTCPK: BWVI) Is Pioneering A Possible Solution
By Faith Ashmore, Benzinga 
Via TheNewswire.com
Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
Australia: Enveric, FSD Pharma, Psyence & Others Advance Businesses 
Via Benzinga
Breakthrough Treatment For PTSD? This Ketamine Cream Showing Promise In Alleviating Symptoms
Biotech company Psycheceutical Bioscience Inc. 
Via Benzinga
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
This year’s edition of the Benzinga Psychedelics Capital Conference, THE place to be for those interested or already involved in the space, will take place on April 13, following our established... 
Via Benzinga
Benzinga's Psychedelics Capital Conference: Meet An Unrivaled Group Of Advisors And Fund Partners
The upcoming Psychedelics Capital Conference constitutes Benzinga’s effort to provide an exclusive opportunity to meet, connect with and learn from some of the most knowledgeable people in the space. 
Via Benzinga
Psycheceutical Bioscience, Inc (OTCPK: BWVI) Could Be Revolutionizing Psychedelic Health Care By Developing The First Ever Topical Psychedelic Cream To Treat PTSD
By Julian Richard, Benzinga 
Via TheNewswire.com
Psycheceutical Bioscience, Inc (OTCPK: BWVI) Could Be Revolutionizing Psychedelic Health Care By Developing The First Ever Topical Psychedelic Cream To Treat PTSD
Psycheceutical Bioscience, Inc (OTCPK: BWVI) Could Be Revolutionizing Psychedelic Health Care By Developing The First Ever Topical Psychedelic Cream To Treat PTSD 
Via News Direct
BioMedNewsBreaks – Psycheceutical Bioscience Inc. (BWVI) Inks Agreement for First-Ever Clinical Trials of a Proprietary Ketamine Topical Cream to Treat PTSD
Via Investor Brand Network
Exposures Product Safety
Novel Ketamine Topical Cream To Treat PTSD Gets First In-Human Trials
Psycheceutical Bioscience (OTCPK: BWVI) is advancing its proprietary ketamine topical formulation into clinical studies. The life sciences company has partnered with Australian-based contract research... 
Via Benzinga
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.